DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway

Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy is rarely reported. We exami...

Full description

Saved in:
Bibliographic Details
Published inCancer cell international Vol. 22; no. 1; p. 106
Main Authors Tong, Zhuting, Fang, Weiyang, Xu, Meng, Xia, YeYe, Wang, Rui, Li, Yue, Zha, Tianqi, Xiao, Liang, Pan, Shuhao, Chai, Huiping, Zhao, Lei, Wang, Hao, Pan, Huaguang, Chen, Xiangcun
Format Journal Article
LanguageEnglish
Published England BioMed Central 05.03.2022
BMC
Subjects
ASK1
Chemoradiosensitivity
DAB2IP
Esophageal squamous cell carcinoma
JNK
Primary Research
DAB2IP
Chemoradiosensitivity
Esophageal squamous cell carcinoma
ASK1
JNK
Online AccessGet full text

Cover

Abstract Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy is rarely reported. We examined the expression dynamics of DAB2IP by immunohistochemistry (IHC) in 140 ESCC patients treated with definitive chemoradiotherapy. A series of in vivo and in vitro experiments were performed to elucidate the effect of DAB2IP on the chemoradiotherapy (CRT) response and its underlying mechanisms in ESCC. Decreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Furthermore, the therapeutic sensitivity of CRT was substantially increased by ectopic overexpression of DAB2IP in ESCC cells. In addition, knockdown of DAB2IP dramatically enhanced resistance to CRT in ESCC. Finally, we demonstrated that DAB2IP regulates ESCC cell radiosensitivity through enhancing ionizing radiation (IR)-induced activation of the ASK1-JNK signaling pathway. Our data highlight the molecular etiology and clinical significance of DAB2IP in ESCC, which may represent a new therapeutic strategy to improve therapy and survival for ESCC patients.
AbstractList BACKGROUNDDisabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy is rarely reported. METHODSWe examined the expression dynamics of DAB2IP by immunohistochemistry (IHC) in 140 ESCC patients treated with definitive chemoradiotherapy. A series of in vivo and in vitro experiments were performed to elucidate the effect of DAB2IP on the chemoradiotherapy (CRT) response and its underlying mechanisms in ESCC. RESULTSDecreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Furthermore, the therapeutic sensitivity of CRT was substantially increased by ectopic overexpression of DAB2IP in ESCC cells. In addition, knockdown of DAB2IP dramatically enhanced resistance to CRT in ESCC. Finally, we demonstrated that DAB2IP regulates ESCC cell radiosensitivity through enhancing ionizing radiation (IR)-induced activation of the ASK1-JNK signaling pathway. CONCLUSIONSOur data highlight the molecular etiology and clinical significance of DAB2IP in ESCC, which may represent a new therapeutic strategy to improve therapy and survival for ESCC patients.
Abstract Background Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy is rarely reported. Methods We examined the expression dynamics of DAB2IP by immunohistochemistry (IHC) in 140 ESCC patients treated with definitive chemoradiotherapy. A series of in vivo and in vitro experiments were performed to elucidate the effect of DAB2IP on the chemoradiotherapy (CRT) response and its underlying mechanisms in ESCC. Results Decreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Furthermore, the therapeutic sensitivity of CRT was substantially increased by ectopic overexpression of DAB2IP in ESCC cells. In addition, knockdown of DAB2IP dramatically enhanced resistance to CRT in ESCC. Finally, we demonstrated that DAB2IP regulates ESCC cell radiosensitivity through enhancing ionizing radiation (IR)-induced activation of the ASK1-JNK signaling pathway. Conclusions Our data highlight the molecular etiology and clinical significance of DAB2IP in ESCC, which may represent a new therapeutic strategy to improve therapy and survival for ESCC patients.
Abstract Background Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy is rarely reported. Methods We examined the expression dynamics of DAB2IP by immunohistochemistry (IHC) in 140 ESCC patients treated with definitive chemoradiotherapy. A series of in vivo and in vitro experiments were performed to elucidate the effect of DAB2IP on the chemoradiotherapy (CRT) response and its underlying mechanisms in ESCC. Results Decreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Furthermore, the therapeutic sensitivity of CRT was substantially increased by ectopic overexpression of DAB2IP in ESCC cells. In addition, knockdown of DAB2IP dramatically enhanced resistance to CRT in ESCC. Finally, we demonstrated that DAB2IP regulates ESCC cell radiosensitivity through enhancing ionizing radiation (IR)-induced activation of the ASK1-JNK signaling pathway. Conclusions Our data highlight the molecular etiology and clinical significance of DAB2IP in ESCC, which may represent a new therapeutic strategy to improve therapy and survival for ESCC patients.
Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy is rarely reported. We examined the expression dynamics of DAB2IP by immunohistochemistry (IHC) in 140 ESCC patients treated with definitive chemoradiotherapy. A series of in vivo and in vitro experiments were performed to elucidate the effect of DAB2IP on the chemoradiotherapy (CRT) response and its underlying mechanisms in ESCC. Decreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Furthermore, the therapeutic sensitivity of CRT was substantially increased by ectopic overexpression of DAB2IP in ESCC cells. In addition, knockdown of DAB2IP dramatically enhanced resistance to CRT in ESCC. Finally, we demonstrated that DAB2IP regulates ESCC cell radiosensitivity through enhancing ionizing radiation (IR)-induced activation of the ASK1-JNK signaling pathway. Our data highlight the molecular etiology and clinical significance of DAB2IP in ESCC, which may represent a new therapeutic strategy to improve therapy and survival for ESCC patients.
ArticleNumber 106
Author Pan, Huaguang
Fang, Weiyang
Tong, Zhuting
Chai, Huiping
Pan, Shuhao
Zhao, Lei
Wang, Rui
Xiao, Liang
Zha, Tianqi
Li, Yue
Xia, YeYe
Chen, Xiangcun
Xu, Meng
Wang, Hao
Author_xml – sequence: 1
  givenname: Zhuting
  orcidid: 0000-0002-5915-7331
  surname: Tong
  fullname: Tong, Zhuting
  email: zhuting_tong@ahmu.edu.cn
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. zhuting_tong@ahmu.edu.cn
– sequence: 2
  givenname: Weiyang
  surname: Fang
  fullname: Fang, Weiyang
  organization: Department of Electrocardiography, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 3
  givenname: Meng
  surname: Xu
  fullname: Xu, Meng
  organization: Department of Oncology, Changhai Hospital, The Second Military Medical University, Shanghai, China
– sequence: 4
  givenname: YeYe
  surname: Xia
  fullname: Xia, YeYe
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 5
  givenname: Rui
  surname: Wang
  fullname: Wang, Rui
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 6
  givenname: Yue
  surname: Li
  fullname: Li, Yue
  organization: Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou, China
– sequence: 7
  givenname: Tianqi
  surname: Zha
  fullname: Zha, Tianqi
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 8
  givenname: Liang
  surname: Xiao
  fullname: Xiao, Liang
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 9
  givenname: Shuhao
  surname: Pan
  fullname: Pan, Shuhao
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 10
  givenname: Huiping
  surname: Chai
  fullname: Chai, Huiping
  organization: Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 11
  givenname: Lei
  surname: Zhao
  fullname: Zhao, Lei
  organization: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
– sequence: 12
  givenname: Hao
  surname: Wang
  fullname: Wang, Hao
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 13
  givenname: Huaguang
  surname: Pan
  fullname: Pan, Huaguang
  organization: Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
– sequence: 14
  givenname: Xiangcun
  surname: Chen
  fullname: Chen, Xiangcun
  email: chenxc@mail.ustc.edu.cn
  organization: Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. chenxc@mail.ustc.edu.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35248066$$D View this record in MEDLINE/PubMed
BookMark eNpVks1u1DAUhSNURH_gBVggL9kE_BM7zgapDAWGVoAorC3Hvpm4ytiD7RTN-_CgeGZK1S4sX91z_F3LPqfVkQ8equolwW8IkeJtIrRjvMaUlsVL1T2pTkjT8ppK0R49qI-r05RuMCatFPhZdcw4bSQW4qT6--H8PV1-R5sI1pmcUI6g8xp8RhHSJvgESHtb9LDyIbmEwoAurhcLtNHZFVvay-tg50lnSMiVTtTWhQQ-uexuXd6iPMYwr0YEftTeOL9Cyx-183Y2YJE2xVVgwe_YeQR0fn1J6i9fL3czxj96-7x6OugpwYu7_az69fHi5-JzffXt03JxflUbLrpci5aaTkrCeitbIlirdYNpb6jt-yJpYpq-wd3AMYWhp1qynnGjmdCWt2LA7KxaHrg26Bu1iW6t41YF7dS-EeJK6ZidmUBZ6GThg6ANb7gBCQPpygiOhWktZYX17sDazP0arClPFfX0CPpY8W5Uq3CrpOzKL5ECeH0HiOH3DCmrtUsGpkl7CHNSVDBRvJTIYqUHq4khpQjD_RiC1S4q6hAVVaKi9lFRXTn06uEF74_8zwb7B2hyv18
CitedBy_id crossref_primary_10_1038_s41418_024_01332_3
crossref_primary_10_1007_s11033_024_09653_9
crossref_primary_10_3389_fimmu_2024_1332942
crossref_primary_10_1007_s00210_024_03163_y
crossref_primary_10_1016_j_isci_2023_107606
Cites_doi 10.1016/j.jbior.2012.09.006
10.1074/jbc.C100466200
10.1016/j.ijrobp.2009.10.037
10.1073/pnas.96.15.8511
10.1517/14656566.2013.801454
10.1158/1078-0432.CCR-18-3004
10.1080/09553000802662595
10.21037/jtd.2017.03.39
10.1080/09553009414550041
10.1172/JCI200317790
10.1083/jcb.151.7.1381
10.1161/CIRCRESAHA.107.168153
10.1038/cdd.2016.134
10.1038/onc.2011.254
10.1038/onc.2016.4
10.2147/OTT.S289722
10.1080/09553002.2016.1257831
10.1002/ijc.20531
10.1016/j.semradonc.2010.05.004
10.1074/jbc.M311129200
10.1136/gut.2010.231993
10.2307/3579809
10.4103/0973-1482.146073
10.3322/caac.21492
10.1038/bjc.2013.81
10.1093/emboj/17.9.2596
10.1038/nm.2100
10.1158/1078-0432.CCR-04-0713
10.2147/OTT.S178131
10.1073/pnas.0908458106
10.1158/0008-5472.CAN-09-2919
10.1002/ijc.27930
10.1158/0008-5472.CAN-15-0088
10.1016/j.ijrobp.2014.03.035
10.1016/j.cellsig.2015.09.014
10.1172/JCI11947
10.1593/neo.121310
10.1006/geno.2002.6739
10.1016/j.jhep.2006.11.012
10.1074/jbc.M407617200
10.1002/ijc.25031
10.1038/onc.2009.382
10.1074/jbc.M110568200
10.1002/jmri.25934
10.1126/science.275.5296.90
ContentType Journal Article
Copyright 2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1186/s12935-022-02535-9
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1475-2867
EndPage 106
ExternalDocumentID oai_doaj_org_article_de987aae624545ce8ef19ca1506c7d23
10_1186_s12935_022_02535_9
35248066
Genre Journal Article
GrantInformation_xml – fundername: the National Natural Science Foundation of China
  grantid: 81201743
– fundername: University Natural Science Research Project of Anhui Province
  grantid: KJ2021A0295
– fundername: Natural Science Foundation of Anhui Province
  grantid: 1908085QA27
– fundername: ;
  grantid: KJ2021A0295
– fundername: ;
  grantid: 81201743
– fundername: ;
  grantid: 1908085QA27
GroupedDBID ---
-56
-5G
-A0
-BR
0R~
29B
2WC
3V.
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
ISR
ITC
KQ8
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
AAYXX
CITATION
7X8
AFGXO
5PM
ID FETCH-LOGICAL-c569t-672c98813bd871637aa402bc2dbb72ca1c4b409f502efb2a83b35ca36ad576f03
IEDL.DBID RPM
ISSN 1475-2867
IngestDate Fri Oct 04 13:10:42 EDT 2024
Tue Sep 17 21:27:55 EDT 2024
Sat Aug 17 02:55:22 EDT 2024
Thu Sep 12 17:26:44 EDT 2024
Sat Sep 28 08:21:47 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords DAB2IP
Chemoradiosensitivity
Esophageal squamous cell carcinoma
ASK1
JNK
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c569t-672c98813bd871637aa402bc2dbb72ca1c4b409f502efb2a83b35ca36ad576f03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5915-7331
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897861/
PMID 35248066
PQID 2636889218
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_de987aae624545ce8ef19ca1506c7d23
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8897861
proquest_miscellaneous_2636889218
crossref_primary_10_1186_s12935_022_02535_9
pubmed_primary_35248066
PublicationCentury 2000
PublicationDate 2022-03-05
PublicationDateYYYYMMDD 2022-03-05
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-05
  day: 05
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Cancer cell international
PublicationTitleAlternate Cancer Cell Int
PublicationYear 2022
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References H Zhang (2535_CR32) 2004; 279
Y Liu (2535_CR35) 2001; 107
EH Goldman (2535_CR36) 2004; 279
M Nakajima (2535_CR3) 2013; 14
Z Wang (2535_CR5) 2002; 277
J Zhou (2535_CR9) 2016; 35
LB Schultz (2535_CR28) 2000; 151
L Zhang (2535_CR33) 1999; 96
MY Cai (2535_CR18) 2011; 60
PA Riley (2535_CR41) 1994; 65
B Hofstetter (2535_CR25) 2010; 76
RL Camp (2535_CR22) 2004; 10
CL Donohoe (2535_CR26) 2017; 9
Z Kong (2535_CR6) 2010; 70
W Ji (2535_CR10) 2015; 75
D Sun (2535_CR17) 2018; 11
LR He (2535_CR20) 2010; 127
L Yu (2535_CR11) 2012; 14
ZT Tong (2535_CR19) 2012; 31
S Burma (2535_CR29) 2001; 276
M Saitoh (2535_CR39) 1998; 17
H Zheng (2535_CR2) 2018; 48
LM Cockrell (2535_CR34) 2010; 29
D Xie (2535_CR31) 2009; 106
F Bray (2535_CR1) 2018; 68
R Zhang (2535_CR37) 2003; 111
JX Zhang (2535_CR21) 2013; 132
RE Meyn (2535_CR30) 2009; 85
H Ichijo (2535_CR38) 1997; 275
A Bellazzo (2535_CR45) 2017; 24
C Jacobs (2535_CR14) 2014; 89
GH Qiu (2535_CR8) 2007; 46
EJ Yun (2535_CR13) 2019; 25
A Sak (2535_CR27) 2010; 20
M Yano (2535_CR7) 2005; 113
H Chen (2535_CR4) 2002; 79
K Wu (2535_CR15) 2015; 27
S Shiizaki (2535_CR40) 2013; 53
SS Wallace (2535_CR42) 1998; 150
J Min (2535_CR24) 2010; 16
R Dayal (2535_CR43) 2014; 10
R Chang (2535_CR12) 2017; 93
G Wang (2535_CR16) 2021; 14
ZT Tong (2535_CR23) 2013; 108
W Min (2535_CR44) 2008; 102
References_xml – volume: 53
  start-page: 135
  issue: 1
  year: 2013
  ident: 2535_CR40
  publication-title: Adv Biol Regul
  doi: 10.1016/j.jbior.2012.09.006
  contributor:
    fullname: S Shiizaki
– volume: 276
  start-page: 42462
  issue: 45
  year: 2001
  ident: 2535_CR29
  publication-title: J Biol Chem
  doi: 10.1074/jbc.C100466200
  contributor:
    fullname: S Burma
– volume: 76
  start-page: 1512
  issue: 5
  year: 2010
  ident: 2535_CR25
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2009.10.037
  contributor:
    fullname: B Hofstetter
– volume: 96
  start-page: 8511
  issue: 15
  year: 1999
  ident: 2535_CR33
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.96.15.8511
  contributor:
    fullname: L Zhang
– volume: 14
  start-page: 1345
  issue: 10
  year: 2013
  ident: 2535_CR3
  publication-title: Expert Opin Pharmacother
  doi: 10.1517/14656566.2013.801454
  contributor:
    fullname: M Nakajima
– volume: 25
  start-page: 4542
  issue: 14
  year: 2019
  ident: 2535_CR13
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-3004
  contributor:
    fullname: EJ Yun
– volume: 85
  start-page: 107
  issue: 2
  year: 2009
  ident: 2535_CR30
  publication-title: Int J Radiat Biol
  doi: 10.1080/09553000802662595
  contributor:
    fullname: RE Meyn
– volume: 9
  start-page: E282
  issue: 3
  year: 2017
  ident: 2535_CR26
  publication-title: J Thorac Dis
  doi: 10.21037/jtd.2017.03.39
  contributor:
    fullname: CL Donohoe
– volume: 65
  start-page: 27
  issue: 1
  year: 1994
  ident: 2535_CR41
  publication-title: Int J Radiat Biol
  doi: 10.1080/09553009414550041
  contributor:
    fullname: PA Riley
– volume: 111
  start-page: 1933
  issue: 12
  year: 2003
  ident: 2535_CR37
  publication-title: J Clin Investig
  doi: 10.1172/JCI200317790
  contributor:
    fullname: R Zhang
– volume: 151
  start-page: 1381
  issue: 7
  year: 2000
  ident: 2535_CR28
  publication-title: J Cell Biol
  doi: 10.1083/jcb.151.7.1381
  contributor:
    fullname: LB Schultz
– volume: 102
  start-page: 840
  issue: 7
  year: 2008
  ident: 2535_CR44
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.107.168153
  contributor:
    fullname: W Min
– volume: 24
  start-page: 15
  issue: 1
  year: 2017
  ident: 2535_CR45
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2016.134
  contributor:
    fullname: A Bellazzo
– volume: 31
  start-page: 583
  issue: 5
  year: 2012
  ident: 2535_CR19
  publication-title: Oncogene
  doi: 10.1038/onc.2011.254
  contributor:
    fullname: ZT Tong
– volume: 35
  start-page: 4663
  issue: 35
  year: 2016
  ident: 2535_CR9
  publication-title: Oncogene
  doi: 10.1038/onc.2016.4
  contributor:
    fullname: J Zhou
– volume: 14
  start-page: 979
  year: 2021
  ident: 2535_CR16
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S289722
  contributor:
    fullname: G Wang
– volume: 93
  start-page: 386
  issue: 4
  year: 2017
  ident: 2535_CR12
  publication-title: Int J Radiat Biol
  doi: 10.1080/09553002.2016.1257831
  contributor:
    fullname: R Chang
– volume: 113
  start-page: 59
  issue: 1
  year: 2005
  ident: 2535_CR7
  publication-title: Int J Cancer
  doi: 10.1002/ijc.20531
  contributor:
    fullname: M Yano
– volume: 20
  start-page: 223
  issue: 4
  year: 2010
  ident: 2535_CR27
  publication-title: Semin Radiat Oncol
  doi: 10.1016/j.semradonc.2010.05.004
  contributor:
    fullname: A Sak
– volume: 279
  start-page: 10442
  issue: 11
  year: 2004
  ident: 2535_CR36
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M311129200
  contributor:
    fullname: EH Goldman
– volume: 60
  start-page: 967
  issue: 7
  year: 2011
  ident: 2535_CR18
  publication-title: Gut
  doi: 10.1136/gut.2010.231993
  contributor:
    fullname: MY Cai
– volume: 150
  start-page: S60
  issue: 5 Suppl
  year: 1998
  ident: 2535_CR42
  publication-title: Radiat Res
  doi: 10.2307/3579809
  contributor:
    fullname: SS Wallace
– volume: 10
  start-page: 811
  issue: 4
  year: 2014
  ident: 2535_CR43
  publication-title: J Cancer Res Ther
  doi: 10.4103/0973-1482.146073
  contributor:
    fullname: R Dayal
– volume: 68
  start-page: 394
  issue: 6
  year: 2018
  ident: 2535_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
  contributor:
    fullname: F Bray
– volume: 108
  start-page: 1470
  issue: 7
  year: 2013
  ident: 2535_CR23
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.81
  contributor:
    fullname: ZT Tong
– volume: 17
  start-page: 2596
  issue: 9
  year: 1998
  ident: 2535_CR39
  publication-title: EMBO J
  doi: 10.1093/emboj/17.9.2596
  contributor:
    fullname: M Saitoh
– volume: 16
  start-page: 286
  issue: 3
  year: 2010
  ident: 2535_CR24
  publication-title: Nat Med
  doi: 10.1038/nm.2100
  contributor:
    fullname: J Min
– volume: 10
  start-page: 7252
  issue: 21
  year: 2004
  ident: 2535_CR22
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0713
  contributor:
    fullname: RL Camp
– volume: 11
  start-page: 7699
  year: 2018
  ident: 2535_CR17
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S178131
  contributor:
    fullname: D Sun
– volume: 106
  start-page: 19878
  issue: 47
  year: 2009
  ident: 2535_CR31
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0908458106
  contributor:
    fullname: D Xie
– volume: 70
  start-page: 2829
  issue: 7
  year: 2010
  ident: 2535_CR6
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-09-2919
  contributor:
    fullname: Z Kong
– volume: 132
  start-page: 2567
  issue: 11
  year: 2013
  ident: 2535_CR21
  publication-title: Int J Cancer
  doi: 10.1002/ijc.27930
  contributor:
    fullname: JX Zhang
– volume: 75
  start-page: 3492
  issue: 17
  year: 2015
  ident: 2535_CR10
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-15-0088
  contributor:
    fullname: W Ji
– volume: 89
  start-page: 729
  issue: 4
  year: 2014
  ident: 2535_CR14
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2014.03.035
  contributor:
    fullname: C Jacobs
– volume: 27
  start-page: 2515
  issue: 12
  year: 2015
  ident: 2535_CR15
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2015.09.014
  contributor:
    fullname: K Wu
– volume: 107
  start-page: 917
  issue: 7
  year: 2001
  ident: 2535_CR35
  publication-title: J Clin Investig
  doi: 10.1172/JCI11947
  contributor:
    fullname: Y Liu
– volume: 14
  start-page: 1203
  issue: 12
  year: 2012
  ident: 2535_CR11
  publication-title: Neoplasia
  doi: 10.1593/neo.121310
  contributor:
    fullname: L Yu
– volume: 79
  start-page: 573
  issue: 4
  year: 2002
  ident: 2535_CR4
  publication-title: Genomics
  doi: 10.1006/geno.2002.6739
  contributor:
    fullname: H Chen
– volume: 46
  start-page: 655
  issue: 4
  year: 2007
  ident: 2535_CR8
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.11.012
  contributor:
    fullname: GH Qiu
– volume: 279
  start-page: 44955
  issue: 43
  year: 2004
  ident: 2535_CR32
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M407617200
  contributor:
    fullname: H Zhang
– volume: 127
  start-page: 138
  issue: 1
  year: 2010
  ident: 2535_CR20
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25031
  contributor:
    fullname: LR He
– volume: 29
  start-page: 822
  issue: 6
  year: 2010
  ident: 2535_CR34
  publication-title: Oncogene
  doi: 10.1038/onc.2009.382
  contributor:
    fullname: LM Cockrell
– volume: 277
  start-page: 12622
  issue: 15
  year: 2002
  ident: 2535_CR5
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110568200
  contributor:
    fullname: Z Wang
– volume: 48
  start-page: 349
  issue: 2
  year: 2018
  ident: 2535_CR2
  publication-title: J Magn Reson Imaging
  doi: 10.1002/jmri.25934
  contributor:
    fullname: H Zheng
– volume: 275
  start-page: 90
  issue: 5296
  year: 1997
  ident: 2535_CR38
  publication-title: Science
  doi: 10.1126/science.275.5296.90
  contributor:
    fullname: H Ichijo
SSID ssj0017860
Score 2.3509462
Snippet Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of...
Abstract Background Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular...
BACKGROUNDDisabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and...
Abstract Background Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 106
SubjectTerms ASK1
Chemoradiosensitivity
DAB2IP
Esophageal squamous cell carcinoma
JNK
Primary Research
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOil9F33hQq9FRNbsmTpuNkm5EFDaRrITejl7h4qh_WGkv_TH9oZy7tkS6GXHgxGEpLwN2JmrJlvCPnAhW2t1LaU3sUS9HVdauFFqUHZOytt2yrMRv58Lo8vm9MrcXWn1BfGhGV64Pzh9kMEr9jaKFkDyt5HFbtae4vEeL4NLPN81mLjTE33B62S1SZFRsn9AbUaZiIzeAS86R01NLL1_83E_DNS8o7qOXpEHk42I53lvT4m92J6Qu7nKpK3T8mvT7MDdvKFXq_w0mU90G3wOF3lCNhIbQoUQ7FSPywH2nf08GI-pxOp6jB2_-gDlvKKA11Cy8qGZT9gdHsuL0Gngj40pgVSdKTv9ORrCQ49iEagmB2R_-3i3GBT0tnFWV2enp_hGouf9vYZuTw6_DY_LqfiC6UXUq9L2TKvlaq5C-hTccAAXE3nWXAOumztGwe-YScqFjvHrOKOC2-5tAFcmK7iz8le6lN8SSjXookBoK9l1-AI0VW2arxjaHx2siAfN1iY68yxYUbfREmTkTOAnBmRM7ogBwjXdiTyY48NIDVmkhrzL6kpyPsN2AbOE16S2BT7m8EwyaVSGiyfgrzI4G-XAvltFNhoBWl3xGJnL7s9abkYObthSpDJ-tX_2Pxr8oCNooyRl2_I3np1E9-CabR278ZT8Bs7WA8s
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELZKEagviLOES0biDQUSX7EfENourXqoFaKs1LfIV7orQVKSrWD_Dz-UsZPdsmifeIgU-RxlvtHMxOMZhN5QrgstlE6FNT4FfZ2nilueKlD2RgtdFDLcRj49E4cTdnzBL7bQstzR8AG7ja5dqCc1ab-9-_Vj8REE_kMUeCned0FnhXvGBB4Ob-oWuk0YZQHxp-zmVKGQIltenNk4bwfdBRqZzGLSxBs9FdP5b7JB_w2l_Es3HdxH9wajEo96FDxAW75-iO70ZSYXj9DvT6M9cvQZX7XhVGbe4VV0OW77EFmPde1wiNWqm27W4abC--fjMR6yrnax-3vjQq0v3-EZtLTazZouhL_39SfwUPEH-3oacnjUl_joSwoeP2DH4XB9ov_5G9YGoxOPzk_y9PjsJOwx_akXj9HkYP_r-DAdqjOklgs1T0VBrJIyp8YFp4sWWoMvaixxxkCXzi0z4DxWPCO-MkRLaii3mgrtwMepMvoEbddN7Z8iTBVn3gE2clGxMIJXmc6YNSRYp5VI0NslL8qrPglHGZ0XKcqeiSUwsYxMLFWC9gK7ViNDAu3Y0LSX5SCPpfNKAsVeEAY2pPXSV7kConkmbOEITdDrJbNLELhwiqJr31x3JRFUSKnANErQbs_81VZL8CSoWIPFGi3rPfVsGpN6w5IAz_zZf898jnZIhHKIx3yBtufttX8JBtPcvIpS8AcDqRa7
  priority: 102
  providerName: Scholars Portal
Title DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway
URI https://www.ncbi.nlm.nih.gov/pubmed/35248066
https://search.proquest.com/docview/2636889218
https://pubmed.ncbi.nlm.nih.gov/PMC8897861
https://doaj.org/article/de987aae624545ce8ef19ca1506c7d23
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBa7Wwq9lL7XfQQVeive2JIly8ckzbIPEkK2C6EXI8nyxtDYwc5S9v_0h3Yk22lTeurBxlh-DMwnZkb6ZgahT5TJWPJE-lwr44O9Dv2EaeYnYOyV5DKOhc1Gns35xW10tWKrI8T6XBhH2teqOCu_b87KYu24lduNHvY8seFiNhECYh8eDo_RcUxpH6J3WwcwEvTZMYIPG2vQbBIygYPBla0TCoJEInCVEX8bI1ez_1-O5t98yT8M0Pkz9LTzHPGolfA5OjLlC_S47SX58BL9_DIak8sF3tZ262XX4D2FHNctD9ZgWWbYErLKqikaXOV4ejOZ4K60auOGN1VmG3qZBhdwp5ZZUTWW4942mcBdWx9syrUt1FHe4culD2E9ACTDNkeiXeG13wbPEo9urkP_an5t_7H-IR9eodvz6dfJhd-1YPA148nO5zHRiRAhVZmNrGgsJQScSpNMKRiSoY4URIg5C4jJFZGCKsq0pFxmEMjkAX2NTsqqNKcI04RFJgMAhDyP7BMsD2QQaUWsC5pzD33udZFu20obqYtQBE9bJaagxNQpMU08NLbq2j9pq2S7G1V9l3ZYSTOTCJDYcBKBo6iNMHmYgNAs4DrOCPXQx17ZKcwqu1UiS1PdNynhlAPKwP_x0JtW-ftf9eDxUHwAiwNZDkcAyK5ydwfct__95jv0hDgoW9Lle3Syq-_NB_CKdmoAc2EVD9Cj8XS-WA7c2gKcZ5GA83L8beBmyS-etBSa
link.rule.ids 230,315,733,786,790,870,891,2115,2236,24346,27955,27956,31753,33778,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6VIgQX3g_zXCRuyIm99q7tYxpaJU0TVbRFva325caC2FGcCJXfww9ldm0HUnGBQ6TI48QT7beamew33yD0IaIiESwTPlPS-BCvQz-jivoZBHspmEiS1HYjT2dsdBEfX9LLPUS7XhhH2ley6JXfFr2ymDtu5XKh-h1PrH86HaYp1D4s7N9Ct2G_EtoV6e3hAdiCrj8mZf3ahjTbhkzgReGdVQoFV-I0cNqIv8ORU-3_W6p5kzH5Rwg6eoC-dM43zJOvvc1a9tSPG7qO__zrHqL7bVKKB435Edoz5WN0pxlTef0E_fw0OCDjU7xc2VOddY237HS8aii2BotSY8v1Kqu6qHGV48Oz4RC3qq21My8qbWeFmRoXcGUldFHVlj7fzK_A7cQgbMq51QApr_D4s1-UGrCnsW2_aP48tt8NSSsenE1C_3g2sc-YfxfXT9HF0eH5cOS30x18RVm29llCVJamYSS1LdqiRAioZaUiWkowiVDFEorPnAbE5JKINJIRVSJiQkONlAfRM7RfVqV5gXCU0dhowFbI8tjeQfNABLGSxGa3OfPQx26R-bIR8eCu-EkZb9DBAR3coYNnHjqwONjeaQW43YVqdcXbheLaZCl4bBiJIQdVJjV5mIHTNGAq0STy0PsORRw2rD2FEaWpNjUnLGKwxJBaeeh5g6rtozpUeijZwduOL7sWQJETBW9R8_K_P_kO3R2dT0_4yXg2eYXuEbdfLLfzNdpfrzbmDSRfa_nWbbVfLQMxQA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgCMQL90G5Gok3lCZxYid57LpV68qqijFp4sXyLWsETaqmFRq_hx_KsZOUdeJpD5Gi2Ilt-bPOOfHn7yD0KaIiESwTHlPSeGCvQy-jinoZGHspmEiS1J5GPp2y4_P45IJeXEv15Uj7Shb98ueiXxZzx61cLpTf8cT82ekwTSH2YaG_1Ll_F92DNUuSLlBvNxCgPOjOyKTMr61Zs0eRCVwU7qxaKHQnTgOnj_jPJDnl_v-5mzdZk9fM0Ogx-t4NoGGf_Ohv1rKvft_QdrzVCJ-gR61zigdNlafojimfoftNusqr5-jP4eCAjGd4ubK7O-sab1nqeNVQbQ0WpcaW81VWdVHjKsdHZ8MhbtVba1e8qLTNGWZqXMCTldBFVVsafZPHAreZg7Ap51YLpLzE469eUWrAoMb2GEbzE9l-G5xXPDibhN7JdGLbmP8SVy_Q-ejo2_DYa7M8eIqybO2xhKgsTcNIahu8RYkQENNKRbSUUCRCFUsIQnMaEJNLItJIRlSJiAkNsVIeRPtor6xK8wrhKKOx0YCxkOWxrUHzQASxksR6uTnroc_dRPNlI-bBXRCUMt4ghANCuEMIz3rowGJhW9MKcbsH1eqSt5PFtclS6LFhJAZfVJnU5GEGnaYBU4kmUQ997JDEYeHa3RhRmmpTc8IiBtMMLlYPvWyQtW2qQ2YPJTuY2-nLbgkgyYmDt8h5fes3P6AHs8MR_zKeTt6gh8QtGUvxfIv21quNeQc-2Fq-d6vtL5q1M8A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=DAB2IP+predicts+treatment+response+and+prognosis+of+ESCC+patients+and+modulates+its+radiosensitivity+through+enhancing+IR-induced+activation+of+the+ASK1-JNK+pathway&rft.jtitle=Cancer+cell+international&rft.au=Tong%2C+Zhuting&rft.au=Fang%2C+Weiyang&rft.au=Xu%2C+Meng&rft.au=Xia%2C+YeYe&rft.date=2022-03-05&rft.pub=BioMed+Central&rft.eissn=1475-2867&rft.volume=22&rft_id=info:doi/10.1186%2Fs12935-022-02535-9&rft_id=info%3Apmid%2F35248066&rft.externalDBID=PMC8897861
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon